When I saw AUPH in the 2's the week Ariad was acquired and realized that the deaths which investors were concerned about were likely not directly attributable to Voclosporin, it struck me how similar this was to the "dirty drug" Ponatinib which has saved thousands of lives. At a very low mc and with a potential 1.5 billion drug about to start phase 3, AUPH remains a screaming bargain. If the 48 week phase 2B data reveals SAEs which are manageable and continued superior efficacy, I may double my shares especially if the sp declines on the news which will not be a surprise to me. The lack of institutional investing will end if the 48 week data is as good as I hope and think it may be. Management is excellent with a ceo who understands lupus nephritis better than anyone. An interesting company and the only one with just one product I have ever bet on. Good luck to you and all of us, because if I am wrong about the deaths not being attributable (directly) by Voclosporin, look out below.
News 
Market Data 
Discover 
AI
